Relay Therapeutics (RLAY) Projected to Release Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Relay Therapeutics to announce earnings of ($0.3964) per share and revenue of $1.62 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.96 million. On average, analysts expect Relay Therapeutics to post ($1.61) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

Relay Therapeutics Price Performance

RLAY opened at $18.35 on Monday. Relay Therapeutics has a 52 week low of $5.95 and a 52 week high of $21.27. The business has a fifty day simple moving average of $18.52 and a 200-day simple moving average of $14.95. The firm has a market cap of $4.02 billion, a P/E ratio of -11.69 and a beta of 1.74.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the transaction, the insider owned 21,904,963 shares in the company, valued at approximately $424,956,282.20. This represents a 21.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Bergstrom sold 8,530 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.97, for a total value of $161,814.10. Following the completion of the sale, the insider owned 399,130 shares in the company, valued at approximately $7,571,496.10. This trade represents a 2.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,149,344 shares of company stock worth $119,185,625 over the last three months. 5.04% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on RLAY shares. Wall Street Zen cut shares of Relay Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, October 2nd. The Goldman Sachs Group lifted their price target on shares of Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Citigroup reaffirmed a “market outperform” rating on shares of Relay Therapeutics in a research report on Monday, August 10th. Finally, Barclays increased their price objective on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites.

The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways.